Exicure, Inc. (XCUR) — SEC Filings
Exicure, Inc. (XCUR) — 50 SEC filings. Latest: 10-K (Mar 25, 2026). Includes 29 8-K, 6 10-Q, 4 DEF 14A.
View Exicure, Inc. on SEC EDGAR
Overview
Exicure, Inc. (XCUR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: EXICURE, INC. (XCUR) reported a significant strategic shift in 2025, moving away from its historical biotechnology focus. The company halted all research and development in September 2022 and began exploring strategic alternatives. In February 2024, XCUR received a $500,000 upfront payment from a li
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 6 bearish, 40 neutral, 4 mixed. The dominant filing sentiment for Exicure, Inc. is neutral.
Filing Type Overview
Exicure, Inc. (XCUR) has filed 3 10-K, 29 8-K, 6 10-Q, 4 DEF 14A, 1 S-1, 2 8-K/A, 1 SC 13D, 3 SC 13D/A, 1 10-Q/A with the SEC between Apr 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of XCUR's 49 recent filings, 10 were flagged as high-risk, 21 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Andy Yoo
- Margaret I. Butler
- Dr. David J. Earp
- Dr. David R. Walt
- Dr. Robert J. T. H. Davies
- Jeongseok Jay Yu
- Daniel S. Clevenger
- Dr. David E. Bearss
- Dr. Richard A. Miller
- Dr. David J. Eby
- Kyungwon Oh
- Jonathan Park
Industry Context
Exicure has undergone a significant strategic pivot, moving away from its historical biotechnology focus on nucleic acid therapies. The company has divested its legacy intellectual property and acquired GPCR Therapeutics USA Inc., entering a new domain. This shift places it in a different competitive landscape, now influenced by the dynamics of the acquired company's therapeutic area, likely within the broader pharmaceutical and biopharmaceutical sectors.
Top Tags
regulatory-filing (6) · corporate-governance (6) · material-agreement (6) · sec-filing (6) · Biotechnology (5) · 8-K (5) · delisting (5) · pharmaceuticals (5) · filing (4) · financial-statements (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common stock held by non-affiliates | $16.4 million | as of June 30, 2025, based on a closing price of $7.04 per share |
| Shares of common stock outstanding | 6,373,915 | as of March 17, 2026 |
| Upfront payment from licensing agreement | $500,000 | received in February 2024 for patents related to a historical drug candidate |
| Other income from sale of samples | $637,000 | recognized in the second quarter of 2024 |
| Other income from sale of historical biotechnology intellectual property | $1,500,000 | recognized in the third quarter of 2024 |
| Milestone payment to GPCR | $1,000,000 | due in Q2 2026 in common stock, following GPCR USA's Phase 2 clinical trial completion |
| Purchase price for 433,333 shares by HiTron | $1.3 million | in November 2024 at $3.00 per share |
| Purchase price for 2,900,000 additional shares by HiTron | $8.7 million | in December 2024 at $3.00 per share |
| Beneficial ownership of outstanding common stock by HiTron | 25% | as of March 17, 2026 |
| Net Loss (Q3 2025) | $2.437M | Increased from $1.091M in Q3 2024 |
| Net Loss (9M 2025) | $2.048M | Improved from $2.520M in 9M 2024 due to lease termination gain |
| Revenue (9M 2025) | $0 | Decreased from $500K in 9M 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $4.438M | Decreased from $12.508M at Dec 31, 2024 |
| Gain on early lease termination (9M 2025) | $5.974M | Significant one-time gain impacting net loss |
| Acquisition cost of GPCR USA | $1.600M | Paid on January 19, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Exicure, Inc. (XCUR)?
Exicure, Inc. has 50 recent SEC filings from Apr 2024 to Mar 2026, including 29 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XCUR filings?
Across 50 filings, the sentiment breakdown is: 6 bearish, 40 neutral, 4 mixed. The dominant sentiment is neutral.
Where can I find Exicure, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Exicure, Inc. (XCUR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Exicure, Inc.?
Key financial highlights from Exicure, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XCUR?
The investment thesis for XCUR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Exicure, Inc.?
Key executives identified across Exicure, Inc.'s filings include Andy Yoo, Margaret I. Butler, Dr. David J. Earp, Dr. David R. Walt, Dr. Robert J. T. H. Davies and 7 others.
What are the main risk factors for Exicure, Inc. stock?
Of XCUR's 49 assessed filings, 10 were flagged high-risk, 21 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Exicure, Inc.?
Forward guidance and predictions for Exicure, Inc. are extracted from SEC filings as they are enriched.